Literature DB >> 2239370

Fluoride bioavailability from slow-release sodium fluoride given with calcium citrate.

C Y Pak1, K Sakhaee, C Parcel, J Poindexter, B Adams, A Bahar, R Beckley.   

Abstract

Clinical pharmacology of slow-release sodium fluoride given with calcium citrate was examined in acute and long-term studies. Following a single oral administration of 50 mg slow-release sodium fluoride, a peak serum fluoride concentration (Cmax) of 184 ng/ml was reached in 2 h; thereafter, serum fluoride concentration declined with a T1/2 of 5.9 h. The concurrent administration of calcium citrate (400 mg calcium) gave an equivalent Tmax (time required to attain Cmax) and T1/2, but a lower Cmax of 135 ng/ml. The coadministration of a meal with fluoride also reduced Cmax but increased Tmax. The area under the serum concentration curve of slow-release sodium fluoride was reduced 17-27% by a meal or calcium citrate. Thus, calcium citrate reduced fluoride absorption and peak fluoride concentration in serum of slow-release sodium fluoride but did not affect the time required to reach peak concentration or the rate of subsequent decline. The effect of a meal was similar, except for a longer period required to reach peak serum concentration. During long-term administration of 25 mg slow-release sodium fluoride coadministered with 400 mg calcium as calcium citrate on a twice daily schedule, the trough level of serum fluoride could be kept between 95 and 190 ng/ml, believed to be the therapeutic window.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2239370     DOI: 10.1002/jbmr.5650050809

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  3 in total

1.  Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis.

Authors:  N Morabito; A Gaudio; A Lasco; C Vergara; F Tallarida; G Crisafulli; A Trifiletti; M Cincotta; M A Pizzoleo; N Frisina
Journal:  Osteoporos Int       Date:  2003-05-15       Impact factor: 4.507

2.  Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.

Authors:  Jochen Klaus; Max Reinshagen; Katharina Herdt; Christoph Schröter; Guido Adler; Georg Bt von Boyen; Christian von Tirpitz
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

3.  Comparison of serum fluoride levels after administration of monofluorophosphate-calcium carbonate or sodium fluoride: differences in peak serum concentrations.

Authors:  L Erlacher; H Teufelsbauer; P Bernecker; P Pietschmann; M Weissel
Journal:  Clin Investig       Date:  1994-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.